Additional file 3: of Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing–remitting multiple sclerosis at year 1

Figure S2. Post hoc analysis of MRI endpoints. (PDF 170 kb)